PDCD1 and neoplasm: It has shown complete responses in animals treated in combination with tumor-infiltrating lymphocytes, Chimeric Antigen Receptor (CAR) T cells, or immune checkpoint inhibitors anti-PD-1 and anti-PD-L1 [10,11,12,13].